MOLECULAR PARTNERS AG
MOLNMolecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development.
Drugs in Pipeline
12
Phase 3 Programs
2
Upcoming Catalysts
4
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
4 upcoming, 1 past
How MOLN's past catalysts played out
MP0420
COVID-19
4D-150 IVT (3E10 vg/eye)
Macular Neovascularization Secondary to Age-Related Macular Degeneration
MP0250 plus BOR+DEX
Multiple Myeloma in Relapse
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1
Leukemia
[212Pb]Pb-MP0712
Large Cell Neuroendocrine Carcinoma
4D-310
Fabry Disease
ATL-001 (Ciclopirox oral solution)
Congenital Erythropoietic Porphyria (CEP)
PMD-026
Metastatic Breast Cancer
Imatinib
Chronic Phase Chronic Myeloid Leukemia
MP0250
Neoplasms
4D-150 IVT
Neovascular (Wet) Age-Related Macular Degeneration
ensovibep
Covid19
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MP0420 | Phase 3 | COVID-19 | - | - |
4D-150 IVT (3E10 vg/eye) | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | - | - |
MP0250 plus BOR+DEX | Phase 2 | Multiple Myeloma in Relapse | - | - |
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1 | Phase 2 | Leukemia | - | - |
[212Pb]Pb-MP0712 | Phase 2 | Large Cell Neuroendocrine Carcinoma | - | - |
4D-310 | Phase 2 | Fabry Disease | - | - |
ATL-001 (Ciclopirox oral solution) | Phase 2 | Congenital Erythropoietic Porphyria (CEP) | - | - |
PMD-026 | Phase 2 | Metastatic Breast Cancer | - | - |
Imatinib | Phase 2 | Chronic Phase Chronic Myeloid Leukemia | - | - |
MP0250 | Phase 2 | Neoplasms | - | - |
4D-150 IVT | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
ensovibep | Phase 2 | Covid19 | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MOLECULAR PARTNERS AG's drug pipeline?→
CatalystAlert tracks 12 drug candidates in MOLECULAR PARTNERS AG's (MOLN) pipeline across Phase 3, Phase 2. Its lead program is MP0420 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MOLECULAR PARTNERS AG's next FDA catalyst?→
MOLECULAR PARTNERS AG's (MOLN) next tracked catalyst is a Earnings expected August 24, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MOLN biotech catalysts?→
Add MOLN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MOLECULAR PARTNERS AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.